CA2657847A1 - Method for predicting protein aggregation and designing aggregation inhibitors - Google Patents

Method for predicting protein aggregation and designing aggregation inhibitors Download PDF

Info

Publication number
CA2657847A1
CA2657847A1 CA002657847A CA2657847A CA2657847A1 CA 2657847 A1 CA2657847 A1 CA 2657847A1 CA 002657847 A CA002657847 A CA 002657847A CA 2657847 A CA2657847 A CA 2657847A CA 2657847 A1 CA2657847 A1 CA 2657847A1
Authority
CA
Canada
Prior art keywords
protein
aggregation
peptide
residues
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002657847A
Other languages
English (en)
French (fr)
Inventor
Kai J. Kohlhoff
Jesus Zurdo
Michele Vendruscolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Biologics PLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2657847A1 publication Critical patent/CA2657847A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
CA002657847A 2006-08-04 2007-07-24 Method for predicting protein aggregation and designing aggregation inhibitors Abandoned CA2657847A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82155306P 2006-08-04 2006-08-04
US60/821,553 2006-08-04
PCT/GB2007/002789 WO2008015384A1 (en) 2006-08-04 2007-07-24 Method for predicting protein aggregation and designing aggregation inhibitors

Publications (1)

Publication Number Publication Date
CA2657847A1 true CA2657847A1 (en) 2008-02-07

Family

ID=38573441

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002657847A Abandoned CA2657847A1 (en) 2006-08-04 2007-07-24 Method for predicting protein aggregation and designing aggregation inhibitors

Country Status (11)

Country Link
US (1) US8290713B2 (https=)
EP (1) EP2047393A1 (https=)
JP (1) JP2009545756A (https=)
KR (1) KR20090047470A (https=)
CN (1) CN101501694B (https=)
AU (1) AU2007280282B2 (https=)
CA (1) CA2657847A1 (https=)
EA (1) EA016884B1 (https=)
IL (1) IL196551A (https=)
SG (1) SG173405A1 (https=)
WO (1) WO2008015384A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
GB2455102A (en) * 2007-11-28 2009-06-03 Cambridge Entpr Ltd Protein Aggregation Prediction Systems
WO2009128948A1 (en) 2008-04-17 2009-10-22 Peptimmune, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
CN107677828A (zh) * 2008-10-31 2018-02-09 耶鲁大学 子痫前期检测和治疗的方法和组合物
AU2010310895A1 (en) * 2009-10-23 2012-05-03 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
FI20105629A0 (fi) * 2010-06-03 2010-06-03 Estaja Oy Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US20120108904A1 (en) * 2010-10-20 2012-05-03 Yong Ma Cleaner for endoscope
CN103772487B (zh) * 2012-10-24 2015-11-25 国家纳米科学中心 一种抑制人胰淀素聚集或毒性的多肽、试剂及其应用
US9618524B2 (en) * 2014-03-26 2017-04-11 Plaxgen Inc. Method, composition, isolation and identification of a plaque particle and related biomarker
CN104502219B (zh) * 2014-12-18 2017-09-29 江苏大学 一种淀粉样多肽聚集抑制剂及其抑制效果评估和验证方法
EP3242955B1 (en) 2015-01-06 2020-05-06 North Carolina State University Modeling ribosome dynamics to optimize heterologous protein production
GB201600176D0 (en) * 2016-01-06 2016-02-17 Cambridge Entpr Ltd Method of identifying novel protein aggregation inhibitors based on chemical kinetics
CA3011719A1 (en) * 2016-01-21 2017-07-27 Protein Dynamic Solutions Llc Method and system for spectral data analysis
US10815271B2 (en) * 2016-06-29 2020-10-27 The Regents Of The University Of California Structure-based peptide inhibitors of alpha-synuclein aggregation
CN106501550A (zh) * 2016-12-09 2017-03-15 江苏大学 基于原子力显微镜氨基酸影响鱼蛋白聚集行为的评价方法
CN111653310B (zh) * 2020-06-29 2023-06-20 北京大学深圳研究生院 含二硫键多肽的结构预测方法及装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781044B2 (en) * 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
CA2528627A1 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of protein aggregation disorders
GB0325817D0 (en) 2003-11-05 2003-12-10 Univ Cambridge Tech Method and apparatus for assessing polypeptide aggregation

Also Published As

Publication number Publication date
WO2008015384A1 (en) 2008-02-07
IL196551A0 (en) 2009-11-18
AU2007280282A1 (en) 2008-02-07
EA200970180A1 (ru) 2009-08-28
JP2009545756A (ja) 2009-12-24
SG173405A1 (en) 2011-08-29
AU2007280282B2 (en) 2012-02-02
CN101501694A (zh) 2009-08-05
US20100160602A1 (en) 2010-06-24
CN101501694B (zh) 2011-11-30
EA016884B1 (ru) 2012-08-30
IL196551A (en) 2013-01-31
US8290713B2 (en) 2012-10-16
WO2008015384A8 (en) 2008-05-15
KR20090047470A (ko) 2009-05-12
HK1131239A1 (en) 2010-01-15
EP2047393A1 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
AU2007280282B2 (en) Method for predicting protein aggregation and designing aggregation inhibitors
Louros et al. Structure-based machine-guided mapping of amyloid sequence space reveals uncharted sequence clusters with higher solubilities
Shell et al. A test on peptide stability of AMBER force fields with implicit solvation
Yoon et al. Detecting hidden sequence propensity for amyloid fibril formation
Sommer et al. Structure-guided isoform identification for the human transcriptome
Fatafta et al. A brief history of amyloid aggregation simulations
Hong et al. Rare disease genomics and precision medicine
Szczepski et al. AlphaFold and what is next: bridging functional, systems and structural biology
Linh et al. Impact of mutations at C-terminus on structures and dynamics of Aβ40 and Aβ42: a molecular simulation study
Black et al. Evaluating calmodulin–protein interactions by rapid photoactivated cross-linking in live cells metabolically labeled with photo-methionine
Sitarik et al. A widespread protein misfolding mechanism is differentially rescued in vitro by chaperones based on gene essentiality
Jakubek et al. Polyglutamine solution-state structural propensity is repeat length dependent
Tastan et al. Comparison of stability predictions and simulated unfolding of rhodopsin structures
Liang et al. Structures and Dynamics of β-Rich Oligomers of ATTR (105–115) Assembly
Patel et al. Mechanistic insights from replica exchange molecular dynamics simulations into mutation induced disordered-to-ordered transition in Hahellin, a βγ-crystallin
Duan et al. Performance of Hybrid Strategies Combining MDockPP and AlphaFold2 in CAPRI Rounds 47–55
Betancourt A reduced protein model with accurate native‐structure identification ability
Heinze et al. CASP10–BCL:: Fold efficiently samples topologies of large proteins
Pantoja-Uceda et al. The NMR structure and dynamics of the two-domain tick carboxypeptidase inhibitor reveal flexibility in its free form and stiffness upon binding to human carboxypeptidase B
HK1131239B (en) Method for predicting protein aggregation and designing aggregation inhibitors
Garcia et al. Monomer binding modes of small molecules that modulate the kinetics of hIAPP amyloid formation
Ma et al. Empirical and computational comparison of alternative therapeutic exon skip repairs for Duchenne muscular dystrophy
Mulvaney et al. Cryo‐EM Analysis in CASP16
Aniceto et al. LigExtract: Large-scale Automated Identification of Ligands from Protein Structures in the Protein Data Bank
Loo et al. SKALE: An Interpretable Multiscale Machine Learning Model for Decoding Phase‐Specific Protein Aggregation in Neurodegenerative Proteinopathies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140724